S. Carter and M. Friedman, 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide (DTIC, DIC, NSC-45388)???A new antitumor agent with activity against malignant melanoma, European Journal of Cancer (1965), vol.8, issue.1, pp.85-92, 1972.
DOI : 10.1016/0014-2964(72)90087-4

A. Benson, Epidemiology, disease Progression, and Economic Burden of Colorectal Cancer, Journal of Managed Care Pharmacy, vol.13, issue.6 Supp C, pp.5-18, 2007.
DOI : 10.18553/jmcp.2007.13.s6-c.5

M. Butler, Natural products to drugs: natural product-derived compounds in clinical trials, Natural Product Reports, vol.17, issue.suppl 2, pp.475-516, 2008.
DOI : 10.1007/s00280-008-0720-z

M. Butler and D. Newman, Mother Nature???s gifts to diseases of man: the impact of natural products on anti-infective, anticholestemics and anticancer drug discovery, Prog Drug Res, vol.65, pp.3-44, 2008.
DOI : 10.1007/978-3-7643-8117-2_1

R. Blum and S. Carter, Adriamycin, Annals of Internal Medicine, vol.80, issue.2, pp.249-259, 1974.
DOI : 10.7326/0003-4819-80-2-249

T. Hata, T. Hoshi, K. Kanamori, A. Matsumae, Y. Sano et al., Mitomycin, a new antibiotic from Streptomyces. I, J Antibiot (Tokyo), vol.9, pp.141-146, 1956.

W. Gradishar and J. Cortes, Clinical efficacy and emerging therapeutic utilization of novel taxanes, European Journal of Cancer Supplements, vol.6, issue.10, pp.12-21, 2008.
DOI : 10.1016/S1359-6349(08)71922-0

M. Aapro, V. Minckwitz, and G. , Molecular basis for the development of novel taxanes in the treatment of metastatic breast cancer, European Journal of Cancer Supplements, vol.6, issue.10, pp.3-11, 2008.
DOI : 10.1016/S1359-6349(08)71921-9

C. Scripture, W. Figg, and A. Sparreboom, Paclitaxel chemotherapy: from empiricism to a mechanism-based formulation strategy, Therapeutics and Clinical Risk Management, vol.1, issue.2, pp.107-114, 2005.
DOI : 10.2147/tcrm.

M. Hawkins, P. Soon-shiong, and N. Desai, Protein nanoparticles as drug carriers in clinical medicine, Advanced Drug Delivery Reviews, vol.60, issue.8, pp.876-885, 2008.
DOI : 10.1016/j.addr.2007.08.044

J. Wong, A. Brugger, A. Khare, M. Chaubal, P. Papadopoulos et al., Suspensions for intravenous (IV) injection: A review of development, preclinical and clinical aspects, Advanced Drug Delivery Reviews, vol.60, issue.8, pp.939-954, 2008.
DOI : 10.1016/j.addr.2007.11.008

S. Nicum, O. Brien, and M. , Topotecan for the treatment of small-cell lung cancer, Expert Review of Anticancer Therapy, vol.7, issue.6, pp.795-801, 2007.
DOI : 10.1586/14737140.7.6.795

M. Marty, P. Fumoleau, A. Adenis, Y. Rousseau, Y. Merrouche et al., Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors, Annals of Oncology, vol.12, issue.11, pp.1643-1649, 2001.
DOI : 10.1023/A:1013180903805

J. Jassem, R. Ramlau, H. Karnicka-mlodkowska, K. Krawczyk, M. Krzakowski et al., A multicenter randomized phase II study of oral vs. intravenous vinorelbine in advanced non-smallcell lung cancer patients, Annals of Oncology, vol.12, issue.10, pp.1375-1381, 2001.
DOI : 10.1023/A:1012539225493

J. Aisner, Overview of the changing paradigm in cancer treatment: Oral chemotherapy, American Journal of Health-System Pharmacy, vol.64, issue.9 Supplement 5, pp.4-7, 2007.
DOI : 10.2146/ajhp070035

L. Jensen, K. Osterlind, and C. Rytter, Randomized cross-over study of patient preference for oral or intravenous vinorelbine in combination with carboplatin in the treatment of advanced NSCLC, Lung Cancer, vol.62, issue.1, 2008.
DOI : 10.1016/j.lungcan.2008.02.009

M. Findlay, G. Von-minckwitz, and A. Wardley, Effective oral chemotherapy for breast cancer: pillars of strength, Annals of Oncology, vol.19, issue.2, pp.212-222, 2008.
DOI : 10.1093/annonc/mdm285

D. Bollag, P. Mcqueney, J. Zhu, O. Hensens, L. Koupal et al., Epothilones, a new class of microtubule-stabilizing agents with a taxollike mechanism of action, Cancer Res, vol.55, pp.2325-2333, 1995.

M. Fornier and . Ixabepilone, first in a new class of antineoplastic agents: the natural epothilones and their analogues, Clin Breast Cancer, vol.7, pp.757-763, 2007.

F. Lee, R. Borzilleri, C. Fairchild, A. Kamath, R. Smykla et al., Preclinical discovery of ixabepilone, a highly active antineoplastic agent, Cancer Chemotherapy and Pharmacology, vol.25, issue.Suppl 1, 2008.
DOI : 10.1007/s00280-008-0724-8

F. Lee, R. Smykla, K. Johnston, K. Menard, K. Mcglinchey et al., Preclinical efficacy spectrum and pharmacokinetics of ixabepilone, Cancer Chemotherapy and Pharmacology, vol.25, issue.Suppl, 2008.
DOI : 10.1007/s00280-008-0727-5

K. Altmann and K. Memmert, Epothilones as lead structures for new anticancer drugs ??? pharmacology, fermentation, and structure-activity-relationships, Prog Drug Res, vol.66, pp.275-334, 2008.
DOI : 10.1007/978-3-7643-8595-8_6

D. Soares, A. Escargueil, V. Poindessous, A. Sarasin, A. De-gramont et al., Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743, Proceedings of the National Academy of Sciences, vol.104, issue.32, pp.13062-13067, 2007.
DOI : 10.1073/pnas.0609877104

N. Carter and S. Keam, Trabectedin, Drugs, vol.361, issue.9375, pp.2257-2276, 2007.
DOI : 10.2165/00003495-200767150-00009

T. Simmons, E. Andrianasolo, K. Mcphail, P. Flatt, and W. Gerwick, Marine natural products as anticancer drugs, Mol Cancer Ther, vol.4, pp.333-342, 2005.

S. Singh and F. Pelaez, Biodiversity, chemical diversity and drug discovery, Prog Drug Res, vol.65, pp.143-174, 2008.
DOI : 10.1007/978-3-7643-8117-2_4

A. Mayer and K. Gustafson, Marine pharmacology in 2005???2006: Antitumour and cytotoxic compounds, European Journal of Cancer, vol.44, issue.16, pp.2357-2387, 2005.
DOI : 10.1016/j.ejca.2008.07.001

W. Ma and J. A. Temsirolimus, Temsirolimus, Drugs of Today, vol.43, issue.10, pp.659-669, 2007.
DOI : 10.1358/dot.2007.43.10.1148059

R. Figlin, Mechanisms of Disease: survival benefit of temsirolimus validates a role for mTOR in the management of advanced RCC, Nature Clinical Practice Oncology, vol.12, issue.10, 2008.
DOI : 10.1038/ncponc1173

C. Vezina, A. Kudelski, and S. Sehgal, Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle., The Journal of Antibiotics, vol.28, issue.10, pp.721-726, 1975.
DOI : 10.7164/antibiotics.28.721

C. Hartford and M. Ratain, Rapamycin: Something Old, Something New, Sometimes Borrowed and Now Renewed, Clinical Pharmacology & Therapeutics, vol.431, issue.4, pp.381-388, 2007.
DOI : 10.1038/sj.clpt.6100317

A. Ganesan, The impact of natural products upon modern drug discovery, Current Opinion in Chemical Biology, vol.12, issue.3, pp.306-317, 2008.
DOI : 10.1016/j.cbpa.2008.03.016

J. Fahy, P. Hellier, F. Breillout, and C. Bailly, Vinflunine: Discovery and Synthesis of a Novel Microtubule Inhibitor, Seminars in Oncology, vol.35, pp.3-5, 2008.
DOI : 10.1053/j.seminoncol.2008.01.004

J. Bellmunt, F. Delgado, and C. George, Clinical Activity of Vinflunine in Transitional Cell Carcinoma of the Urothelium and Other Solid Tumors, Seminars in Oncology, vol.35, pp.34-43, 2008.
DOI : 10.1053/j.seminoncol.2008.01.008

T. Kurata, I. Okamoto, K. Tamura, and M. Fukuoka, Amrubicin for non-small-cell lung cancer and small-cell lung cancer, Investigational New Drugs, vol.28, issue.1, pp.499-504, 2007.
DOI : 10.1007/s10637-007-9069-0

L. Pearl, C. Prodromou, and P. Workman, The Hsp90 molecular chaperone: an open and shut case for treatment, Biochemical Journal, vol.410, issue.3, pp.439-453, 2008.
DOI : 10.1042/BJ20071640

Y. Lu, C. Li, and Q. Dong, Chinese herb related molecules of cancer-cell-apoptosis: a minireview of progress between Kanglaite injection and related genes, Journal of Experimental & Clinical Cancer Research, vol.27, issue.1, p.31, 2008.
DOI : 10.1186/1756-9966-27-31

D. Normile, ASIAN MEDICINE: The New Face of Traditional Chinese Medicine, Science, vol.299, issue.5604, pp.188-190, 2003.
DOI : 10.1126/science.299.5604.188

T. Mijatovic, D. Nève, N. Gailly, P. Mathieu, V. Haibe-kains et al., Nucleolus and c-Myc: potential targets of cardenolide-mediated antitumor activity, Molecular Cancer Therapeutics, vol.7, issue.5, pp.1285-1296, 2008.
DOI : 10.1158/1535-7163.MCT-07-2241

I. Petit, M. Karajannis, L. Vincent, L. Young, J. Butler et al., The microtubule-targeting agent CA4P regresses leukemic xenografts by disrupting interaction with vascular cells and mitochondrial-dependent cell death, Blood, vol.111, issue.4, pp.1951-1961, 2008.
DOI : 10.1182/blood-2007-05-089219

L. Pieters and A. Vlietinck, Bioguided isolation of pharmacologically active plant components, still a valuable strategy for the finding of new lead compounds?, Journal of Ethnopharmacology, vol.100, issue.1-2, pp.57-60, 2005.
DOI : 10.1016/j.jep.2005.05.029

J. Mcchesney, S. Venkataraman, and J. Henri, Plant natural products: Back to the future or into extinction?, Phytochemistry, vol.68, issue.14, pp.2015-2022, 2007.
DOI : 10.1016/j.phytochem.2007.04.032

H. Sielaff, G. Christiansen, and T. Schwecke, Natural products from cyanobacteria: Exploiting a new source for drug discovery, IDrugs, vol.9, pp.119-127, 2006.

T. Simmons, R. Coates, B. Clark, N. Engene, D. Gonzalez et al., Biosynthetic origin of natural products isolated from marine microorganism-invertebrate assemblages, Proceedings of the National Academy of Sciences, vol.105, issue.12, pp.4587-4594, 2008.
DOI : 10.1073/pnas.0709851105

G. Lang, N. Mayhudin, M. Mitova, L. Sun, S. Van-der-sar et al., Evolving Trends in the Dereplication of Natural Product Extracts: New Methodology for Rapid, Small-Scale Investigation of Natural Product Extracts, Journal of Natural Products, vol.71, issue.9, 2008.
DOI : 10.1021/np8002222

F. Koehn, High impact technologies for natural products screening, Prog Drug Res, vol.65, pp.177-210, 2008.
DOI : 10.1007/978-3-7643-8117-2_5

A. Harvey, Natural products as a screening resource, Current Opinion in Chemical Biology, vol.11, issue.5, pp.480-484, 2007.
DOI : 10.1016/j.cbpa.2007.08.012

Y. Masuoka, N. Shindoh, and N. Inamura, Histone deacetylase inhibitors from microorganisms: the Astellas experience, Prog Drug Res, vol.66, pp.335-337, 2008.
DOI : 10.1007/978-3-7643-8595-8_7

F. Ausseil, A. Samson, Y. Aussagues, I. Vandenberghe, L. Créancier et al., High-Throughput Bioluminescence Screening of Ubiquitin-Proteasome Pathway Inhibitors from Chemical and Natural Sources, Journal of Biomolecular Screening, vol.69, issue.1, pp.106-116, 2007.
DOI : 10.1177/1087057106296494

I. Vandenberghe, L. Créancier, S. Vispé, J. Annereau, J. Barret et al., Physalin B, a novel inhibitor of the ubiquitin-proteasome pathway, triggers NOXA-associated apoptosis, Biochemical Pharmacology, vol.76, issue.4, pp.453-462, 2008.
DOI : 10.1016/j.bcp.2008.05.031

A. Ivascu and M. Kubbies, Rapid Generation of Single-Tumor Spheroids for High-Throughput Cell Function and Toxicity Analysis, Journal of Biomolecular Screening, vol.117, issue.8, pp.922-932, 2006.
DOI : 10.1177/1087057106292763

R. Herrmann, W. Fayad, S. Schwarz, M. Berndtsson, and S. Linder, Screening for Compounds That Induce Apoptosis of Cancer Cells Grown as Multicellular Spheroids, Journal of Biomolecular Screening, vol.13, issue.1, pp.1-8, 2008.
DOI : 10.1177/1087057107310442

J. Friedrich, R. Ebner, and L. Kunz-schughart, Experimental anti-tumor therapy in 3-D: Spheroids ??? old hat or new challenge?, International Journal of Radiation Biology, vol.10, issue.11-12, pp.849-871, 2007.
DOI : 10.1007/s10456-004-8911-7

H. Tian, L. Ip, H. Luo, D. Chang, and K. Luo, A high throughput drug screen based on fluorescence resonance energy transfer (FRET) for anticancer activity of compounds from herbal medicine, British Journal of Pharmacology, vol.4, issue.3, pp.321-334, 2007.
DOI : 10.1038/sj.bjp.0706988

R. Orlowski and D. Kuhn, Proteasome Inhibitors in Cancer Therapy: Lessons from the First Decade, Clinical Cancer Research, vol.14, issue.6, pp.1649-57, 2008.
DOI : 10.1158/1078-0432.CCR-07-2218

A. Roccaro, A. Vacca, and D. Ribatti, Bortezomib in the Treatment of Cancer, Recent Patents on Anti-Cancer Drug Discovery, vol.1, issue.3, pp.397-403, 2006.
DOI : 10.2174/157489206778776925

D. Chauhan, A. Singh, M. Brahmandam, K. Podar, T. Hideshima et al., Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma, Blood, vol.111, issue.3, pp.1654-1664, 2008.
DOI : 10.1182/blood-2007-08-105601

D. Kuhn, Q. Chen, P. Voorhees, J. Strader, K. Shenk et al., Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma, Blood, vol.110, issue.9, pp.3281-3290, 2007.
DOI : 10.1182/blood-2007-01-065888

B. Moore, A. Eustáquio, and R. Mcglinchey, Advances in and applications of proteasome inhibitors, Current Opinion in Chemical Biology, vol.12, issue.4, pp.434-440, 2008.
DOI : 10.1016/j.cbpa.2008.06.033

M. Groll, B. Schellenberg, A. Bachmann, C. Archer, R. Huber et al., A plant pathogen virulence factor inhibits the eukaryotic proteasome by a novel mechanism, Nature, vol.59, issue.7188, pp.755-758, 2008.
DOI : 10.1038/nature06782

C. Coleman, J. Rocetes, D. Park, C. Wallick, B. Warn-cramer et al., Syringolin A, a new plant elicitor from the phytopathogenic bacterium Pseudomonas syringae pv. syringae, inhibits the proliferation of neuroblastoma and ovarian cancer cells and induces apoptosis, Cell Proliferation, vol.154, issue.6, pp.599-609, 2006.
DOI : 10.1074/jbc.M204962200

B. Dorsey, M. Iqbal, S. Chatterjee, E. Menta, R. Bernardini et al., Discovery of a Potent, Selective, and Orally Active Proteasome Inhibitor for the Treatment of Cancer, Journal of Medicinal Chemistry, vol.51, issue.4, pp.1068-1072, 2008.
DOI : 10.1021/jm7010589

R. Piva, B. Ruggeri, M. Williams, G. Costa, I. Tamagno et al., CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib, Blood, vol.111, issue.5, pp.2765-2775, 2008.
DOI : 10.1182/blood-2007-07-100651

I. Shah, D. Napoli, and M. , The Ubiquitin-Proteasome System and Proteasome Inhibitors in Central Nervous System Diseases, Cardiovascular & Hematological Disorders-Drug Targets, vol.7, issue.4, pp.250-273, 2007.
DOI : 10.2174/187152907782793572

J. Brun, Proteasome inhibition as a novel therapy in treating rheumatoid arthritis, Medical Hypotheses, vol.71, issue.1, pp.65-72, 2008.
DOI : 10.1016/j.mehy.2008.02.014

B. Teicher, Next generation topoisomerase I inhibitors: Rationale and biomarker strategies, Biochemical Pharmacology, vol.75, issue.6, pp.1262-1271, 2008.
DOI : 10.1016/j.bcp.2007.10.016

F. Rossi, E. Labourier, T. Forné, G. Divita, J. Derancourt et al., Specific phosphorylation of SR proteins by mammalian DNA topoisomerase I, Nature, vol.381, issue.6577, pp.80-82, 1996.
DOI : 10.1038/381080a0

A. Trzci?ska-daneluti, A. Górecki, A. Czubaty, B. Kowalska-loth, A. Girstun et al., RRM Proteins Interacting with the Cap Region of Topoisomerase I, Journal of Molecular Biology, vol.369, issue.4, pp.1098-1112, 2007.
DOI : 10.1016/j.jmb.2007.04.017

B. Pilch, E. Allemand, M. Facompré, C. Bailly, J. Riou et al., Specific inhibition of serine-and arginine-rich splicing factors phosphorylation, spliceosome assembly, and splicing by the antitumor drug NB-506, Cancer Res, vol.61, pp.6876-6884, 2001.

G. Michlewski, J. Sanford, and J. Cáceres, The Splicing Factor SF2/ASF Regulates Translation Initiation by Enhancing Phosphorylation of 4E-BP1, Molecular Cell, vol.30, issue.2, pp.179-189, 2008.
DOI : 10.1016/j.molcel.2008.03.013

J. Sanford, J. Ellis, D. Cazalla, and J. Cáceres, Reversible phosphorylation differentially affects nuclear and cytoplasmic functions of splicing factor 2/alternative splicing factor, Proceedings of the National Academy of Sciences, vol.102, issue.42, pp.15042-15047, 2005.
DOI : 10.1073/pnas.0507827102

R. Karni, E. De-stanchina, S. Lowe, R. Sinha, D. Mu et al., The gene encoding the splicing factor SF2/ASF is a proto-oncogene, Nature Structural & Molecular Biology, vol.66, issue.3, pp.185-193, 2007.
DOI : 10.1038/sj.onc.1202835

M. Muraki, B. Ohkawara, T. Hosoya, H. Onogi, J. Koizumi et al., Manipulation of Alternative Splicing by a Newly Developed Inhibitor of Clks, Journal of Biological Chemistry, vol.279, issue.23, pp.24246-24254, 2004.
DOI : 10.1074/jbc.M314298200

J. Soret, M. Gabut, and J. Tazi, SR Proteins as Potential Targets for Therapy, Prog Mol Subcell Biol, vol.44, pp.65-87, 2006.
DOI : 10.1007/978-3-540-34449-0_4

G. Ismael, D. Rosa, M. Mano, and A. Awada, Novel cytotoxic drugs: Old challenges, new solutions, Cancer Treatment Reviews, vol.34, issue.1, pp.81-91, 2008.
DOI : 10.1016/j.ctrv.2007.08.001

J. Reichert and J. Wenger, Development trends for new cancer therapeutics and vaccines, Drug Discovery Today, vol.13, issue.1-2, pp.30-37, 2008.
DOI : 10.1016/j.drudis.2007.09.003